Alpha Tau Medical Ltd. (DRTS)

Alpha Tau Medical Ltd. (DRTS) Healthcare & Pipeline Overview

Alpha Tau Medical Ltd. is a clinical-stage biotechnology company specializing in diffusing alpha-emitters radiation therapy (Alpha DaRT) for solid cancer treatment. With ongoing clinical trials targeting skin, oral, pancreatic, and breast cancers, Alpha Tau aims to establish a novel radiation therapy option in the oncology market.

What Is the Investment Thesis for DRTS?

Alpha Tau Medical presents a notable research candidate due to its innovative Alpha DaRT technology, which has the potential to revolutionize the treatment of solid tumors. The company's ongoing clinical trials across multiple cancer types, including skin, oral, pancreatic, and breast cancers, represent significant near-term catalysts. Success in these trials could lead to regulatory approvals and commercialization, driving substantial revenue growth. With a market cap of $1.22B and a beta of 1.05, Alpha Tau offers a balance of growth potential and market sensitivity. The company's focus on targeted radiation therapy addresses a critical unmet need in oncology, positioning it for long-term success. However, potential risks include clinical trial setbacks, regulatory hurdles, and competition from established cancer therapies.

Based on FMP financials and quantitative analysis

DRTS Key Highlights

• Alpha Tau Medical is a clinical-stage company focused on Alpha DaRT technology for solid tumor treatment.
• The company's Alpha DaRT is in clinical trials for skin, oral, pancreatic, and breast cancers.
• Preclinical studies are underway for hepatic cell carcinoma, glioblastoma multiforme, and lung cancer.
• Alpha Tau Medical is headquartered in Jerusalem, Israel, with operations in Israel and the United States.
• The company has a market capitalization of $1.22B and employs 125 people.

Who Are DRTS's Competitors?

DRTS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are DRTS's Key Strengths?

• Innovative Alpha DaRT technology.
• Targeted approach minimizes side effects.
• Ongoing clinical trials across multiple cancer types.
• Strong intellectual property protection.

What Are DRTS's Weaknesses?

• Clinical-stage company with no current revenue.
• Reliance on successful clinical trial outcomes.
• Limited commercial infrastructure.
• High research and development costs.

What Could Drive DRTS Stock Higher?

• Interim data readout from ongoing clinical trials for skin cancer in Q3 2026.
• Initiation of Phase 2/3 trial for pancreatic cancer in Q4 2026.
• Enrollment of patients in existing clinical trials for oral and breast cancers.
• Publication of clinical trial results in peer-reviewed journals.
• Potential regulatory submissions for Alpha DaRT in select markets in 2027.

What Are the Key Risks for DRTS?

• Negative return on equity (-73.2%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays could negatively impact the company's development timeline and valuation.
• Regulatory hurdles or rejection of Alpha DaRT could prevent commercialization.
• Competition from established cancer therapies and emerging technologies.
• Product liability claims related to Alpha DaRT.
• Dependence on key personnel and strategic partnerships.

What Are the Growth Opportunities for DRTS?

• Expansion of Clinical Trials: Alpha Tau has the opportunity to expand its clinical trials to include a broader range of solid tumor types and stages. This expansion can increase the potential patient population and accelerate the development of Alpha DaRT as a versatile cancer treatment. The global oncology market is projected to reach $286 billion by 2028, providing a substantial market opportunity for Alpha Tau's technology. Timeline: Ongoing, with new trials initiated in the next 1-3 years.
• Regulatory Approvals: Securing regulatory approvals for Alpha DaRT in key markets, such as the United States and Europe, represents a significant growth catalyst. Approval would enable Alpha Tau to commercialize its technology and generate revenue. The FDA's accelerated approval pathways for breakthrough therapies could expedite the approval process. Timeline: Anticipated within the next 2-4 years, pending clinical trial results.
• Strategic Partnerships: Forming strategic partnerships with pharmaceutical companies and healthcare providers can accelerate the commercialization and adoption of Alpha DaRT. These partnerships can provide access to established distribution networks and clinical expertise. The pharmaceutical industry is increasingly focused on collaborations to develop innovative cancer therapies. Timeline: Ongoing, with potential partnerships announced in the next 1-2 years.
• Technological Advancements: Continued innovation in Alpha DaRT technology, such as improving the delivery and targeting of alpha emitters, can enhance its efficacy and safety. These advancements can expand the potential applications of Alpha DaRT and strengthen its competitive position. The biotechnology industry is characterized by continuous technological innovation. Timeline: Ongoing, with incremental improvements expected over the next 3-5 years.
• Geographic Expansion: Expanding commercial operations to new geographic markets, such as Europe and Asia, can drive revenue growth and increase Alpha Tau's global presence. These markets offer significant opportunities for cancer therapies, driven by aging populations and increasing healthcare spending. The global healthcare market is projected to grow significantly in the coming years. Timeline: Planned expansion within the next 3-5 years, following regulatory approvals.

What Opportunities Does DRTS Have?

• Expansion of clinical trials to new cancer types.
• Regulatory approvals in key markets.
• Strategic partnerships with pharmaceutical companies.
• Technological advancements in Alpha DaRT.

What Threats Does DRTS Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from established cancer therapies.
• Product liability risks.

What Are DRTS's Competitive Advantages?

• Patented Alpha DaRT technology provides a competitive advantage.
• Clinical data demonstrating the safety and efficacy of Alpha DaRT.
• Established relationships with key opinion leaders in oncology.
• Proprietary manufacturing process for Alpha DaRT seeds.

What Does DRTS Do?

Alpha Tau Medical Ltd., founded in 2015 and headquartered in Jerusalem, Israel, is a clinical-stage oncology therapeutics company dedicated to researching, developing, and commercializing the Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) technology. Alpha DaRT is designed for the treatment of solid tumors by delivering localized alpha radiation directly to the tumor site, sparing surrounding healthy tissue. The company's primary focus is on advancing Alpha DaRT through clinical trials for various cancer types, including skin, oral, pancreatic, and breast cancers. Alpha Tau's technology is based on the insertion of Alpha DaRT seeds directly into the tumor, where they emit short-range alpha particles that induce highly localized cell death. This targeted approach aims to minimize systemic side effects commonly associated with traditional radiation therapies. The company is currently conducting clinical trials in Israel and the United States to evaluate the safety and efficacy of Alpha DaRT in different cancer indications. In addition to its clinical programs, Alpha Tau is also engaged in preclinical studies to explore the potential of Alpha DaRT in treating other types of solid tumors, such as hepatic cell carcinoma, glioblastoma multiforme, and lung cancer. Alpha Tau's mission is to provide a new and effective treatment option for patients with solid tumors, addressing the limitations of existing therapies and improving patient outcomes. The company's focus on innovation and clinical development positions it as a potential leader in the field of targeted radiation therapy.

What Products and Services Does DRTS Offer?

• Develops Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for solid cancer treatment.
• Conducts clinical trials for Alpha DaRT in various cancer types, including skin, oral, pancreatic, and breast cancers.
• Engages in preclinical studies to explore the potential of Alpha DaRT in treating other solid tumors.
• Focuses on delivering localized alpha radiation directly to the tumor site.
• Aims to minimize systemic side effects associated with traditional radiation therapies.
• Seeks regulatory approvals for Alpha DaRT in key markets, such as the United States and Europe.

How Does DRTS Make Money?

• Develops and patents Alpha DaRT technology.
• Conducts clinical trials to demonstrate the safety and efficacy of Alpha DaRT.
• Seeks regulatory approvals to commercialize Alpha DaRT.
• Generates revenue through the sale of Alpha DaRT seeds and related services.

What Industry Does DRTS Operate In?

The biotechnology industry is characterized by rapid innovation and intense competition, particularly in the oncology space. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. Alpha Tau Medical is positioned within the targeted radiation therapy segment, which offers the potential for more effective and less toxic treatments compared to traditional radiation therapy. The company faces competition from established pharmaceutical companies and other biotechnology firms developing novel cancer therapies. Success in this industry requires strong clinical data, regulatory approvals, and effective commercialization strategies.

Who Are DRTS's Key Customers?

• Oncologists and radiation oncologists.
• Hospitals and cancer treatment centers.
• Patients with solid tumors.

FY2026 estForward Outlook

Wall Street analysts project Alpha Tau Medical Ltd. revenue of about $1.2M for fiscal 2026, with EPS near $-0.66.

DRTS Valuation & Market Position

With a $1.22B market cap, Alpha Tau Medical Ltd. sits in the small-cap segment of the market. Relative to its peer group, DRTS's quantitative score of 52/100 is below the peer average of 76/100.

ROE -73%Key Financial Metrics

Return on equity for Alpha Tau Medical Ltd. stands at -73.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -52.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.79 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.3%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Alpha Tau Medical Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 14.81 places it in the safe zone, indicating low near-term bankruptcy risk.

Company Profile

Alpha Tau Medical Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Jerusalem, IL. The company is led by CEO Uzi Sofer. DRTS has traded publicly since 2021.

DRTS Financials

DRTS Latest News

DRTS Analyst Consensus

DRTS MoonshotScore

Alpha Tau Medical Ltd. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources